Aetna modified CPB 0753 covering core decompression for avascular necrosis, effective November 1, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated its core decompression coverage policy under CPB 0753 in the Aetna system. The policy governs reimbursement for HCPCS S2325 (hip core decompression) and a range of adjunctive procedures billed under CPT codes including 0101T, 0232T, 0481T, and 38232. The update sharpens the line between covered and experimental indications — and that line has real claim denial exposure for orthopedic and surgical billing teams.
Quick-Reference: Aetna CPB 0753 Core Decompression Policy (2025)
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Core Decompression for Avascular Necrosis |
| Policy Code | CPB 0753 |
| Change Type | Modified |
| Effective Date | November 1, 2025 |
| Impact Level | High |
| Specialties Affected | Orthopedic surgery, sports medicine, interventional radiology, hematology/oncology |
| Key Action | Audit all core decompression claims for stage documentation — only Ficat Stage I or II femoral head AVN qualifies for coverage under S2325 |
Aetna Core Decompression Coverage Criteria and Medical Necessity Requirements 2025
The Aetna core decompression coverage policy is narrow. Medical necessity applies to exactly one scenario: early-stage avascular necrosis (AVN) of the hip — specifically the femoral head and/or neck — at Ficat Stage I or II, before X-ray changes are evident.
That's it. One joint. Two stages. Everything else is experimental.
Your documentation has to establish pre-collapse status at the time of service. Aetna uses the Ficat Classification to define staging. Under that system, cysts on imaging push a patient into Stage II — still covered. Stage III or higher means post-collapse, and that's where medical necessity ends under this policy.
The practical takeaway: if the operative or diagnostic record doesn't clearly state Ficat staging, your claim for S2325 is exposed. Don't let your billing team submit without that staging language in the supporting documentation. If your practice doesn't routinely document Ficat stage in the surgical note, fix that workflow before November 1, 2025.
Aetna's core decompression billing guidelines don't explicitly call out prior authorization requirements within CPB 0753 itself, but prior auth requirements can vary by plan. Check the member's specific plan documents before scheduling. Assuming no prior auth is required for a surgical procedure is a fast path to a claim denial.
Aetna Core Decompression Exclusions and Non-Covered Indications
This is where CPB 0753 gets long — and where most denials will come from.
Aetna classifies core decompression as experimental, investigational, or unproven for AVN in any joint other than the hip. That means ankle, elbow, knee, mandibular condyle, and shoulder are all excluded. If your orthopedic team performs core decompression at the knee or shoulder and bills it under S2325, expect a denial.
Late-stage hip AVN (Stage III or higher, when X-ray changes have occurred) is also experimental. So is post-arthroscopic osteonecrosis.
The adjunctive treatment exclusion list is extensive. Aetna considers all of the following experimental when used to treat AVN in any joint:
| # | Excluded Procedure |
|---|---|
| 1 | Autologous bone marrow mononuclear cells, bone marrow concentrate, or bone marrow stem cells |
| 2 | Autologous platelet concentrate |
| 3 | Bisphosphonates |
| 4 | Bone morphogenic proteins (e.g., rhBMP-2) |
| 5 | Demineralized bone matrix |
| 6 | Erythropoietin |
| 7 | Extracorporeal shockwave therapy (CPT 0101T) |
| 8 | Growth factors |
| 9 | Intraosseous ibandronate |
| 10 | Laser therapy (HCPCS S8948) |
| 11 | Mesenchymal stem cells |
| 12 | Ozone therapy |
| 13 | Parathyroid hormone |
| 14 | Platelet-rich fibrin |
| 15 | Platelet-rich plasma (CPT 0232T; HCPCS P9020) |
| 16 | PRP combined with stem cells |
| 17 | PRP combined with mesenchymal stem cells and synthetic bone graft |
| 18 | Synthetic bone graft substitutes (e.g., calcium sulphate, calcium phosphate) |
Four additional procedure combinations are explicitly experimental:
| # | Excluded Procedure |
|---|---|
| 1 | Combined core decompression and bone marrow aspiration concentrate grafting, or intralesional autologous BM-derived cell therapies for osteonecrosis of the femoral head |
| 2 | Biological augmentation (bone marrow aspiration concentrates, mesenchymal stem cell derivatives, adipose-derived stromal vascular fraction) with retro-drilling core decompression |
| 3 | Core decompression combined with a biomaterial scaffold (e.g., allograft-bone threaded cage or mineralized collagen threaded scaffold) |
| 4 | Osseoscopy-assisted core decompression and debridement |
The real issue here is the stem cell and PRP combinations. These are being used in practice and marketed aggressively. If your orthopedic or regenerative medicine group has been billing any of these alongside S2325 for Aetna patients, audit those claims now. The bisphosphonate injections — J1436 (etidronate disodium), J1740 (ibandronate sodium), J2430 (pamidronate disodium), J3489 (zoledronic acid) — are also non-covered under this policy.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Early/pre-collapse AVN of the hip, Ficat Stage I or II (femoral head/neck) | Covered | S2325; M87.151–M87.159, M87.251–M87.256, M87.351–M87.353, M87.851–M87.859, M87.51–M87.59, M90.551–M90.559 | Requires documented Ficat staging; verify prior auth by plan |
| Late/post-collapse AVN of the hip, Stage III or higher | Experimental | — | X-ray changes present; not eligible for S2325 |
| AVN of other joints (ankle, elbow, knee, mandibular condyle, shoulder) | Experimental | — | All joints except hip excluded |
| Post-arthroscopic osteonecrosis | Experimental | — | |
| Extracorporeal shockwave therapy for AVN | Experimental | CPT 0101T | Any joint |
| Platelet-rich plasma (PRP) for AVN | Experimental | CPT 0232T; HCPCS P9020 | Any joint |
| Autologous white blood cell concentrate injection | Experimental | CPT 0481T | Any joint |
| Bone marrow harvesting (autologous) as adjunctive AVN treatment | Experimental | CPT 38232 | Any joint |
| Bone marrow harvesting (allogenic) as adjunctive AVN treatment | Experimental | CPT 38230 | Any joint |
| Bisphosphonate injections for AVN | Not Covered | J1436, J1740, J2430, J3489 | All bisphosphonate formulations excluded |
| Intraosseous infusion for AVN | Not Covered | CPT 36680 | |
| Laser therapy for AVN | Not Covered | HCPCS S8948 | |
| Connective tissue (non-human/synthetic) | Not Covered | HCPCS C1763 | |
| Core decompression + bone marrow aspiration concentrate grafting | Experimental | — | Combination excluded |
| Biological augmentation with retro-drilling core decompression | Experimental | — | Includes adipose-derived stromal vascular fraction |
| Core decompression + biomaterial scaffold | Experimental | — | Includes allograft-bone threaded cage, mineralized collagen scaffold |
| Osseoscopy-assisted core decompression and debridement | Experimental | — |
Aetna Core Decompression Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit all active core decompression cases before November 1, 2025. Pull every scheduled or recent case for Aetna patients. Confirm the chart documents Ficat Stage I or II. If staging isn't explicit in the surgical note or pre-op imaging report, get an addendum now. |
| 2 | Add Ficat staging to your documentation templates. If your orthopedic surgeons don't routinely record Ficat stage in operative notes, update the template today. This is the single most important documentation element for S2325 reimbursement under this policy. |
| 3 | Stop billing adjunctive experimental codes alongside S2325 for Aetna patients. If your group has been bundling PRP (0232T or P9020), bone marrow harvesting (38232), or shockwave therapy (0101T) with core decompression for AVN, those adjunctive codes will deny. They were likely denying before — but now the policy language is explicit. |
| 4 | Flag bisphosphonate injection claims. J1436, J1740, J2430, and J3489 are not covered for AVN under this policy. If these are being submitted for Aetna patients as part of an AVN treatment plan, remove them from the claim or expect denial. |
| 5 | Verify prior authorization by plan before scheduling. CPB 0753 doesn't specify a blanket prior auth requirement, but individual Aetna plan designs vary. A denial for missing prior auth on a surgical procedure is worse than a coverage denial — it's often non-recoverable. Call and verify. |
| 6 | Train your front-end team on joint-site eligibility. Core decompression at the knee, shoulder, ankle, or elbow is experimental under this policy. If your surgeons perform these at non-hip sites, don't bill under S2325 for Aetna. This applies to the non-femoral ICD-10 codes in the M87 range as well. |
| 7 | Review related policies for adjacent procedures. If a patient progresses past Stage II, hip arthroplasty under CPB 0287 or joint resurfacing under CPB 0661 may be the appropriate path. Know which policy governs the next step in care. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Core Decompression Under CPB 0753
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| S2325 | HCPCS | Hip core decompression |
Experimental / Not Covered CPT Codes
| Code | Type | Description | Status |
|---|---|---|---|
| 0101T | CPT | Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy | Experimental |
| 0232T | CPT | Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation | Experimental |
| 0481T | CPT | Injection(s), autologous white blood cell concentrate (autologous protein solution), any site | Experimental |
| 38232 | CPT | Bone marrow harvesting for transplantation; autologous | Experimental |
| 36680 | CPT | Placement of needle for intraosseous infusion | Not covered for indications in CPB |
Not Covered HCPCS Codes
| Code | Type | Description |
|---|---|---|
| C1763 | HCPCS | Connective tissue, non-human (includes synthetic) |
| J1436 | HCPCS | Injection, etidronate disodium, per 300 mg |
| J1740 | HCPCS | Injection, ibandronate sodium, 1 mg |
| J2430 | HCPCS | Injection, pamidronate disodium, per 30 mg |
| J3489 | HCPCS | Injection, zoledronic acid, 1 mg |
| P9020 | HCPCS | Platelet rich plasma, each unit |
| S8948 | HCPCS | Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| M87.0 | Osteonecrosis of bone (idiopathic aseptic) |
| M87.00–M87.050; M87.061–M87.150; M87.161–M87.166; M87.174–M87.179; M87.188–M87.219; M87.231–M87.250; M87.261–M87.319; M87.331–M87.350; M87.361–M87.366; M87.374–M87.819; M87.831–M87.850; M87.861–M87.869; M87.874–M87.9; M90.511–M90.549; M90.561–M90.58–M90.59 | Osteonecrosis of bone [excluding femur] — experimental indications |
| M87.151–M87.159 | Osteonecrosis of femur [early/pre-collapse, Stage I or II] — covered under selection criteria |
| M87.251–M87.256 | Osteonecrosis of femur [early/pre-collapse, Stage I or II] — covered under selection criteria |
| M87.351–M87.353 | Osteonecrosis of femur [early/pre-collapse, Stage I or II] — covered under selection criteria |
| M87.51–M87.59 | Osteonecrosis of femur [early/pre-collapse, Stage I or II] — covered under selection criteria |
| M87.851–M87.859 | Osteonecrosis of femur [early/pre-collapse, Stage I or II] — covered under selection criteria |
| M90.551–M90.559 | Osteonecrosis of femur [early/pre-collapse, Stage I or II] — covered under selection criteria |
| M87.1 | Osteonecrosis due to drugs |
| M87.2 | Osteonecrosis due to previous trauma |
| M87.3 | Other secondary osteonecrosis |
| M87.4 | Osteonecrosis of jaw |
| M87.5 | Osteonecrosis in diseases classified elsewhere |
| M87.6 | Osteonecrosis due to hemoglobinopathy |
| M87.7 | Osteonecrosis due to corticosteroid use |
| M87.8 | Other osteonecrosis |
| M87.9 | Osteonecrosis, unspecified |
Get the Full Picture for CPT 38232
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.